Medical Pharmacology Practice
Questions: Recombinant antibody Binding to EGFR : panitumumab (Vectibix)
Click on the correct answer.
Panitumumab (Vectibix):
Recombinant antibody
Fully humanized IgG2κ
Both
Neither
Mechanism of action: panitumumab
Binds to the epidermal growth factor receptor (extracellular domain III)
Inhibits ligand binding which activates downstream signaling.
Both
Neither
Labeled clinical indication(s) of panitumumab:
First-line treatment of SCLC (small cell lung cancer)
Treatment of some patients with an mCRC (metastatic colorectal cancer).
Both
Neither
Treatment option(s) for use of panitumumab in treating metastatic colorectal cancer:
First-line treatment when combined with the FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin)
Single-agent should disease progress following prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing protocols.
Both
Neither
Panitumumab pharmacokinetics:
Nonlinear pharmacokinetic properties.
Approximate half-life is 7 days.
Both
Neither
Panitumumab competitively inhibits epidermal growth factor ligand-binding to its receptor.
True
False
Panitumumab binding to the EGFR:
Inhibits phosphorylation and activation of tyrosine kinases (intracellular).
Inhibits cell growth, proliferation, and transformation.
Both
Neither
Panitumumab is not an indicated treatment for those patients with RAS-mutant and mCRC or when mutational status of RAS is unknown.
True
False
Panitumumab by inhibiting epidermal growth factor may compromise fetal development. Therefore, effective contraception during treatment and for at least two months following the last dose is appropriate for females of reproductive potential.
True
False
Adverse effect/effects associated with panitumumab administration:
